Literature DB >> 30157458

Boston Type 2 keratoprosthesis- mid term outcomes from a tertiary eye care centre in India.

Geetha Iyer1, Bhaskar Srinivasan2, Shweta Agarwal2, Ramya Ravindran2, Ekta Rishi3, Pukhraj Rishi3, Sripriya Krishnamoorthy4.   

Abstract

To analyse the anatomical and functional outcomes of Boston type II keratoprosthesis at a tertiary eye care centre in South India. Retrospective chart review of 10 patients operated with Boston keratoprosthesis Type 2 between Feb 2013 and June 2017 were analysed. Outcome measures analysed included, visual outcome, device retention and postoperative complications. The most common indication for surgery was SJS in 80% (8 of 10 eyes). Mean follow-up duration was 2.75 years (0.5-5 years, SD - 1.71, median 32 months) Postoperative visual acuity improved to better than 20/200 in 7 eyes and better than 20/30 in 6 eyes with device retention in 9 eyes at last follow-up. Pre-existing glaucoma was noted in 1 eye. RPM was noted in 1 eye, retinal detachment in 1 eye, endophthalmitis in 1 eye and sterile melt requiring kpro replacement in 1 eye. No progression or development of glaucoma was noted postoperatively in any eye . Boston type 2 keratoprosthesis is a viable option to restore vision in patients with end stage ocular surface disorders. Though the procedure can be associated with complications, early as well as late, our midterm outcome appears to be encouraging.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Boston keratoprosthesis; Boston keratoprosthesis type 2; Keratoprosthesis; Kpro; Ocular chemical injury; Stevens Johnson syndrome

Mesh:

Year:  2018        PMID: 30157458     DOI: 10.1016/j.jtos.2018.08.003

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  3 in total

1.  Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Boston Keratoprosthesis in Southern China: A Retrospective Study.

Authors:  Yuying Zhang; Zhancong Ou; Jin Zhou; Jiajie Zhai; Jianjun Gu; Jiaqi Chen
Journal:  Adv Ther       Date:  2020-05-20       Impact factor: 3.845

2.  Transscleral Cyclophotocoagulation for the Treatment of Uncontrolled Glaucoma in a Boston Keratoprosthesis Type II Patient.

Authors:  Ana Orive Bañuelos; Begoña Arana Larrea; Alja Crnej; Ana Arce Soto; Noelia Andollo Victoriano; Jaime Etxebarria Ecenarro
Journal:  Case Rep Ophthalmol       Date:  2022-03-17

3.  Recurrent cystoid macular edema following Boston keratoprosthesis type-II implantation: A treatment option.

Authors:  Samar K Basak; Soham Basak
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.